Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The pharmaceutical and biotechnology index decreased by 0.68% this week, underperforming the CSI 300 index by 0.11 percentage points, ranking 19th in industry performance [12] - The healthcare sector has shown significant growth, with the medical services sub-sector increasing by 16.04% year-to-date, while traditional Chinese medicine has the lowest growth at 1.86% [17][19] - The J.P. Morgan Health Conference highlighted the strategic advancements of top global pharmaceutical companies, with over 20 Chinese firms participating, indicating a trend towards overseas collaboration in innovative drugs [34] Summary by Sections Market Review - The pharmaceutical index has risen by 7.08% from the beginning of 2026 to January 16, outperforming the CSI 300 index by 4.88 percentage points, ranking 8th in industry performance [12] - The medical services sub-sector has the highest year-to-date growth at 16.04%, while the lowest is traditional Chinese medicine at 1.86% [19] Individual Stock Performance - In the A-share market, 206 out of 478 pharmaceutical stocks rose, with the top five performers being Baolait (up 48.76%), Hualan Biological (up 32.72%), and Tianzhihang (up 27.67%) [23] - In the Hong Kong market, 59 out of 116 pharmaceutical stocks increased, with Ark Health leading at 51.66% growth [26] Industry News and Policies - The sixth batch of national high-value medical consumables procurement was opened on January 13, with 202 companies winning bids for 440 products [29] - Medtronic announced a strategic partnership with Precision Neuroscience to develop integrated solutions combining their technologies [29] - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its portfolio in peripheral vascular interventions [30] Weekly Insights - The medical services sector's strong performance is attributed to positive revenue growth, with medical commercial and services sectors showing year-on-year revenue increases of 0.56% and 3.99%, respectively [33] - The J.P. Morgan Health Conference served as a significant platform for discussing trends in drug development and investment strategies, with a focus on AI and international collaborations [34]

Core Viewpoint - The collaboration between Precision Neuroscience and Medtronic aims to integrate brain-machine interface technology with surgical navigation systems to enhance clinical applications in neurosurgery, focusing on real-time visualization of brain structure and function during operations [2][4][14]. Group 1: Collaboration Framework - The partnership centers on the integration of Precision Neuroscience's Layer 7 brain-machine interface (BCI) and Medtronic's StealthStation surgical navigation system [4]. - Layer 7 is a flexible cortical electrode array with a thickness of one-fifth of a human hair, featuring 1024 electrodes for high spatial resolution and designed for minimally invasive implantation [6]. - StealthStation provides real-time 3D imaging for precise anatomical localization during cranial and spinal surgeries, becoming essential in complex brain procedures [8]. Group 2: Clinical Application Expansion - The clinical application of brain-machine interface technology is shifting from chronic control to intraoperative assistance, with Layer 7 initially designed for paralyzed patients now being adapted for rapid functional area identification during surgeries [9][10]. - The integration allows for simultaneous visualization of functional and structural data, aiding in high-risk surgical decisions such as tumor removal while preserving critical brain functions [10]. Group 3: Future Trends in Surgical Data Ecosystem - The collaboration indicates a trend towards a closed-loop surgical data ecosystem, connecting functional signals with real-time surgical systems [11][12]. - This integration could lead to the development of personalized brain function models, potentially creating digital brain maps that track functional status before, during, and after surgery [12]. Group 4: Industry Trends and Implications - The partnership reflects a shift from speculative brain-machine interface concepts to practical clinical applications, emphasizing a step-by-step approach to functional mapping in surgery [13][14]. - The collaboration highlights the importance of integrating high-frequency signal processing and AI analysis to enhance predictive capabilities and decision-making in surgical environments [16].